Dr. Harry Richard Reynolds, M.D. Dermatology Medicare: May Accept Medicare Assignments Practice Location: 2345 Chesterfield Ave, Suite 204, Charleston, WV 25304 Phone: 304-345-3570 Fax: 304-345-3599 |
Tara J. Robinson, PA-C Dermatology - Procedural Dermatology Medicare: Accepting Medicare Assignments Practice Location: 108 Washington St W Ste 101, Charleston, WV 25302 Phone: 304-345-4525 Fax: 304-345-4527 |
Dr. Stephen Kirby Milroy, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 3100 Mccorkle Ave Se, Ste 809, Charleston, WV 25304 Phone: 304-345-0280 Fax: 304-346-9727 |
Dr. David Judy, D.O. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 4610 Kanawha Ave Sw, Suite 302, Charleston, WV 25309 Phone: 304-925-7546 Fax: 681-205-8369 |
Dr. Richard Allen Hawkins, M.D. Dermatology - Procedural Dermatology Medicare: Not Enrolled in Medicare Practice Location: 5003a Venable Ave, Charleston, WV 25304 Phone: 304-925-5400 Fax: 304-925-5309 |
News Archive
In his latest Kaiser Health News column, Austin Frakt writes: "With the ambition of reducing the federal debt, Congressman Paul Ryan has offered a proposal to convert Medicare to a voucher-based program.
The program named "Continuum of Care," and led by co-author Cordelia Sharma, M.D., a Geisinger critical care physician, involves redesigning the workflow and delivery of hospital-based care to maximize clinical effectiveness. Similar to the "patient-centered advanced medical home" model, the program emphasizes timely comprehensive and coordinated care that is personalized to the patient's needs and makes use of Geisinger's advanced electronic clinical information system.
Naturally occurring high hemoglobin levels are safe for kidney disease patients on dialysis, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology.
NeoPharm, Inc., announced today that the Office of Orphan Products Development of the United States Food and Drug Administration (FDA) has granted orphan-drug designation for IL13-PE38QQR (IL13-PE) for the treatment of Idiopathic Pulmonary Fibrosis (IPF).
› Verified 1 days ago